ACTRN12614000552684Not yet recruitingPhase 1
A Phase 1 study of Temozolomide, Irinotecan, and O6BG (O6-Benzylguanine) for Children with Recurrent or Resistant Neuroblastoma
The Sydney Children's Hospitals Network0 sites24 target enrollmentStarted: May 22, 2014Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Treatment
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 1 Years to 16 Years (—)
- Sex
- All
Inclusion Criteria
- •*Age - Patients must be 1- 16 years of age at the time of study entry.
- •*Diagnosis - Patients must have had a diagnosis of neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumour cells in the bone marrow with increased urinary catecholamines. Participants are not required to have measurable disease at the time of study entry.
- •*Disease status - Patients must have neuroblastoma with at least ONE of the following:
- •-Recurrent/progressive disease at any time. A new biopsy of current tumour sites is not required to document eligibility.
- •-Resistant disease (i.e. less than a partial response to frontline therapy with minimum of 4 cycles of chemotherapy). No new biopsy is required for eligibility for study for this patient group.
- •-Persistent disease after at least a partial response to frontline therapy (i.e. patient has had at least a partial response to frontline therapy but still has residual disease by MIBG, CT/MRI, or bone marrow). Patients in this category are REQUIRED to have a biopsy of at least one residual site demonstrating viable neuroblastoma. Tumour by routine bone marrow morphology is sufficient for this patient group to verify persistent disease although bone marrow alone is insufficient for eligibility into the study. If biopsy and/or bone marrow aspirate cell detection demonstrates only ganglioneuroma, then patient is not eligible.
- •*Location of disease - Patients must have at least ONE of the following sites of disease:
- •-Tumour on MRI or CT scans or X-ray. For patients with persistent disease, as in point (3) above, a biopsy of site seen on CT/MRI must have demonstrated viable neuroblastoma. If the lesion was radiated, then biopsy must be done > 4 weeks after radiation completed.
- •-MIBG scan with positive uptake at a minimum of one site. For patients with persistent disease, as in point (3) above, a biopsy of an MIBG positive site must demonstrate viable neuroblastoma. If the lesion was irradiated, then biopsy must be done > 4 weeks after radiation completed.
- •-Bone marrow with tumour cells seen on routine morphology (not by immunocytology staining only) of one bone marrow sample of a bilateral aspirate and/or biopsy.
- •*Life Expectancy
- •Must have a life expectancy of at least 8 weeks.
- •*Performance level - Performance will be assessed using a Lansky score which must be greater than or equal to 50% for children less than or equal to 16 years of age. Patients who are unable to walk because of paralysis but who are up and in a wheelchair will be considered ambulatory for the purposes of assessing the performance scale.
- •*Prior Therapy - Patients need to have exhausted standard curative options of therapy.
- •There is no limit to the number of prior regimens allowed. Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
- •-Myelosuppressive chemotherapy and/or biologics: 2 weeks
- •-Autologous stem cell transplant, including non-myeloablative therapy with stem cell support: 6 weeks
- •-Radiotherapy (XRT): No treatment within 2 weeks of study entry. Six week delays are required following large field radiation (TBI, craniospinal, whole abdomen, total lung, >50% marrow space).
- •-MIBG therapy: 6 weeks
- •*Organ Function Requirements
- •1.Adequate Bone Marrow Function Defined as:
- •-Absolute neutrophil count (ANC) > 1,000/microl
- •-Platelets > 100,000/microl (transfusion independent, i
Exclusion Criteria
- •*Pregnancy or Breast-Feeding: Pregnant or lactating females are ineligible as the medications used in this protocol could be harmful to unborn children and infants. Pregnancy tests must be obtained in girls who are post-menarche. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- •*Uncontrolled Infection: Patients who have an uncontrolled active infection are excluded from this study.
- •*Previous Treatment:
- •1. Patients who have previously received allogeneic stem cell transplant are excluded from this study.
- •2. Patients treated with temozolomide and/or irinotecan are able to be treated on this study but not those treated with temozolomide, irinotecan and O6BG.
- •*Other: Patients with diarrhoea at enrolment defined as 3 or more loose stools per day are excluded from this study.
Investigators
Similar Trials
Not yet recruiting
Phase 2
Phase II Trial of Temozolomide and Caelyx in the Treatment of Patients with Glioblastoma Multiforme following concurrent radiotherapy and chemotherapyCancer - BrainGlioblastomaACTRN12607000090415Schering-Plough40
Active, not recruiting
Not Applicable
PHASE I/II STUDY OF TEMOZOLOMIDE COMBINED WITH ORAL ETOPOSIDE IN CHILDREN AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA COHORT A , AND MALIGNANT GLIAL TUMOUR COHORT B - NDRELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA AND MALIGNANT GLIAL TUMOUR IN CHILDREN AND YOUNG ADULTSMedDRA version: 8.1Level: HLTClassification code 10007960Term: Central nervous system neoplasms malignant NECEUCTR2006-000570-78-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI24
Completed
Phase 1
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid TumorsBrain and Central Nervous System TumorsUnspecified Childhood Solid Tumor, Protocol SpecificNCT00138216Children's Oncology Group42
Recruiting
Phase 2
Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study2024-515681-14-00Fondazione IRCCS Istituto Nazionale Dei Tumori25
Unknown
Phase 1
A Phase 1b Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Drug Product in Japanese Subjects With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a FluoropyrimidineJPRN-jRCT2080221386Eli Lilly Japan K.K.